Human genetic now lies at the heart of drug development enriching pipelines with validated candidates and providing decision making tools to reduce failure rates. The field continues to thrive off masses of research and clinical data build evidence in target discovery, validation, patient stratification and safety. This year the festival focusses on aligning you with world class strategy as well as in depth practical insights to make genomics count and deliver benefits to patients.
- How to transforming drug discovery and development with an integrated genomics approach
- Using Omic platforms, molecular libraries, data resources, and AI to unravel disease complexity
- Understand the potential of PGx to develop better, safer medicines
- Using genetic tests to help define drug dose and choice to reduce the likelihood of adverse reactions
- What kinds of genomics based predictive diagnostics are academia developing?
- What performance can a new diagnostic achieve as a commercial product produced by a company?
- How will public healthcare regulate and assess the cost effectiveness of precision medicine drugs?
The release of the CMO’s Generation Genome report focused on the need for the UK to maintain its presence as a world leader in genomic medicine. It presented a vision of genomics being integrated into the NHS within the next 5 years – highlighting the importance of tactical restructures across genetic labs in the UK, collaborations being built between stakeholders & the education of clinical staff, patients & the wider public.
- Join sessions mapping challenges and opportunities for integration of genomics within the NHS.
- Understand the gap between translational implementation and sustained clinical testing - and critically ask – is clinical genomics financially sustainable?
- View data from 10,000 representatives around the globe about public attitudes towards genomic data sharing.
- Learn about the technical challenges facing clinical services and hear from the ACGS on the upcoming changes to address these – from an overview of quality frameworks through to educational initiatives.
- Attend a series of sessions in association with the AGNC exploring what generation genome will mean for genetic counsellors
- Follow through case scenarios to understand how the process of assigning pathogenicity of a copy number variant is applied in a real setting.
- Assess models for improving consent, enabling data analysis and reducing the time and cost associate with interpreting permissible uses of data
Data is pouring out of sequencing machines, through the clouds and pipelines around the world at rates and volumes that are challenging for the community. To mine the insights held within coordinated approaches and action are vital. The best practice for storing, securing and the challenges of sharing, analysing and integrating this in a meaningful and accessible are growing.
- How to best tackle the Integration of complex biodata
- Exploring integrative analysis e.g. health record data, genetics, expression, metabolomics and imaging
- Selecting machine learning approaches to establish phenotype-genotype relationships and integrate multiple data types
- Developing question driven data sets and integrating large data set
- Data visualisation and how to navigate masses of data
- What are the current challenges around the economy of data sharing?
- Where are the business opportunities around the open access of personal genomic data and health?
For months, CRISPR has dominated publications as being simple & easy to use, innovative and adaptable and as offering promise for many untreatable diseases. Despite this hype – there are big questions over how close CRISPR really is to clinical use. This session at the Festival will align perspectives from research, drug development and the clinic to evaluate what obstacles there are to the application of CRISPR in the clinic and will provide key technical updates for those working with CRISPR day to day.
- Learn how Genentech are refining CRISPR as a tool for drug discovery
- Discover how allied technologies (like induced pluripotency, in-vitre gametes & whole genome sequencing) could unlock further potential for CRISPR in the (near!) future
- Assess why editing might be further from the clinic than we think - evaluating political, ethical & technical challenges.
- Be able to answer ‘when can we expect human heritable editing?’ and to understand some of the intricacies around techniques dealing with single vs multi-gene disorder editing.